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INTRODUCTION
For the global community of respiratory disease is a global 
health problem, primarily because of their widespread 
prevalence among the able-bodied population, the con-
stant progression, the development of frequent various 
of extra-pulmonary pathologies and effects. Nowadays 
known probably 80 diseases are cause of CPH. But the 
main cause of progression CPH is СOPD that represents 
a major global challenge. Also it is devastating pathology 
that reduce  patients’ quality of life and is a huge socio-eco-
nomic burden for morbidity and mortality worldwide 
[1,2]. As reported by definition of Havrysyuka V.K. [3], 
CPH is circulatory failure syndrome with the progressing 
of peripheral edema, which complicates the course of 
many diseases with damage to the structure or only lung 
function. There are two types of CPH: compensated as a 
sign of the basic disease and decompensated is a sign of 
peripheral edema. According to modern data in the world 
about 600 millions of patients with COPD that increasing 
with age. Before forecasts of experts, COPD  will take on 
the third place among of structure cause of mortality by 
2020 year [ 4,5,6,7,8 ]. 
According to the results of large screening studies, 
the prevalence of COPD is greater in smokers than in 
non-smokers, in people over 40 years of age more than in 
young people, in men more than in women. At the same 
time, society has little knowledge of this problem and the 
cost of scientific research COPD is in 13th place.
Published articles in European White Book of Lungs 
(2013 year) are once confirms this pattern. Considering 
the high prevalence of COPD, the number of patients 
with CPH as its complication increased. As a result of 
this complication, the mortality rate is 67% and ranks 
third after arterial hypertension (AH), coronary heart 
disease (CHD), particularly among the causes of death of 
persons over 50 years of age. According to the concepts of 
the global strategy of diagnostic, treatment and preven-
tion of COPD (Global Initiative for chronic obstructive 
pulmonary disease, GOLD (2017) [9], COPD is a disease 
with significant extrapulmonary manifestation such as 
arterial hypertension (AH), СHD , metabolic syndrome 
(MS), obesity, etc. They significantly complicate not only 
the course of the disease, but also lead to a deterioration 
in the quality of patient’s life. COPD becomes not only a 
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ABSTRACT
Introduction: Chronic obstructive pulmonary disease (COPD) is the main cause of progression chronic pulmonary heart (CPH), it is a serious worldwide problem. The combination 
of COPD with essential arterial hypertension (EAH) ranges from 4 to 27.7% with increasing age.
The aim: To evaluate endothelium function changes by the level of metabolites of nitric oxide, endothelin-1(ET-1), values of ultrasonic diagnosis of the humeral artery (HA), 
intracardial hemodynamics of the left ventricle in patients with CPH in combination with EAH.
Materials and methods: The research is involved 175 patients. Indicators of endothelial function by the level of nitric oxide metabolites, ET - 1, ultrasound intracardiac 
hemodynamics of the left ventricle of the heart were studied.
Results: The patients with CPH in combination with EAH in compensation stage have reduced level of nitric oxide in comparison with patients with CPH without EAH and 
healthy. To a large extent, reducing of nitric oxide level  in decompensation stage indicates about contribution of combined pathology and requires ED correction. On the contrary 
increased concentration of ET-1 in decompensation stage indicate about combined pathology and demands correction of endothelial cell function.
Conclusions: Thus, patients with CPH in combination with EAH are characterized by more pronounced changes in endothelial dysfunction toward an increase in the level of 
vasoconstrictor factors, a decreasing of vasodilators, which is confirmed by ultrasound diagnosis of HA and reflected in the peculiarities of the intracardiac hemodynamic state.
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pulmonary problem, but also a cardiac due to the frequent 
progressing of cardiovascular comorbid pathology in this 
category of patients [10,11].
The comorbidity of COPD and EAH remains the most im-
portant, their combination ranges from 4 to 27.7%, in the older 
age groups up to 62%, it increasing with age [12]. This has a sig-
nificant impact on health, quality and life expectancy. Recently, 
in the pathogenesis of CPH of bronchial pulmonary genesis, 
AH, CHD pay much attention for studying endothelial dys-
function as a pathogenetic link of these diseases [13,14,15,16]. 
Activation or damage of the endothelium is fundamental in the 
development of a wide range of pathological processes.
THE AIM
To evaluate changes in endothelial function by the level of 
metabolites of nitric oxide, endothelin -1 (ET-1), indicators 
of ultrasound of the humeral artery (HA), intracardiac 
hemodynamics of the left ventricle (LV) in patients with 
CPH of bronchopulmonary genesis in combination with 
essential arterial hypertension (EAH).
MATERIALS AND METHODS
The study involved 96 persons with CPH in combination 
with EAH, II stage (the main group), from their the stage of 
compensation was detected in 32 (33.3%) patients is group 3 
without heart failure (HF), stage of decompensation have 64 
(66.7%) patients is group 4 with signs of HF. The comparative 
group consisted of 64 patients with CPH have identical gen-
der, age, severity of illness of their 32 (50.0%) patients have 
the stage of compensation 0 without signs of HF is group 1 
and 32 (50.0% ) in the stage of decompensation with signs 
of HF is group 2. Thus, were 34 females and 62 males with 
an average age of 57.5 ± 1.2 years. The control group for 
patients with CPH with EAH were 15 healthy identical in 
gender and age. The basis for the causing of CPH was COPD.
The day before, all patients has signed an informed con-
sent to be participation in the research in accordance with 
the requirements of the 1975 Declaration of Helsinki, its 
revision in 1983 and Order of the Ministry of Health of 
Ukraine № 690 of September 23, 2009 «About approval of 
the procedure for conducting clinical trials of medicinal 
products and examination of materials of clinical trials» 
and « The typical provision for ethics committees». Ethical 
and the moral and legal aspects of the research were agreed 
by the commission of bioethics in Ukrainian medical 
stomatological academy.
The total content of the stable metabolites of nitrogen 
oxide was determined in blood serum by the spectro-
photometric method by the set of reactants (Тоtal NO) 
made by “RL-system”, USA in accordance with the kit 
instructions. Determination of ET-1 level was carried out 
by the enzyme immunoassay by the set of reactants BIG 
Endothelin-1 (HUMAN), Peninsula Laboratories inc., 
Division of Bachem.
An Aloca 5000 Pro Sound (Japan) ultrasonic scanner 
with a 13 MHz line sensor according to the D.S. Celermay-
er method was used to measure the diameter of the vessel. 
The research was carried out in the morning fasting before 
taking medicines in a special room. The study of the right 
HA was carried out 2-5 cm above the elbow joint, the cuff of 
the tonometer was applied on the forearm. The diameter of 
HA (mm) was measured in the transverse and longitudinal 
planes in order to obtain the same values to improve mea-
surement accuracy, the location of the sensor was noted. The 
diameter of the HA was defined as the distance between the 
anterior and posterior walls of the artery on the face of the 
vessel intima/flow. The diameter measurement was carried 
out at the finite-diastolic phase of the blood flow, which was 
determined at the moment of appearance of the tooth R on 
the ECG synchronized with the ultrasonic image. Endothe-
lium-dependent vasodilation (EDVD) was determined for 
90 seconds after 5 minutes of shoulder compression with 
300 mm Hg pressure by calculating the percent change in 
artery diameter with initial. Endothelium independent va-
sodilation (EIVD) was determined as the maximum percent 
artery expansion within 5 minutes after sublingual admin-
istration of 0.5 mg of nitroglycerine at minute-by-minute 
registration. The norm considered increasing the diameter 
of vessels more than 10% of the initial and 20% against the 
background of nitroglycerine action.
The assessment of the state of intradermal hemodynam-
ics of LV was carried out using two-dimensional echocar-
diography on Toshiba SSA, 380 A Powervision (Japan) 
according to a conventional technique.
The following parameters were determined: left atrial 
diameter (LA, mm), cardiac (l/min (m2) and percussion 
(ml/m2) indices (CI and PI, respectively), thickness of the 
posterior septum of LV (TPWLV, mm), emission fraction 
(EF,%), maximal rate of transaortal blood flow(Vmax, 
m / s). The diastolic function of LV was evaluated by Dop-
pler investigation of the transmitral blood flow of early 
E (m/s) and late A (m/s), their E/A ratio (conventional 
units), isovolumic relaxation time (IVRT) and the size of 
the interventricular septum (IVS, mm). 
The criteria for diagnostics COPD were approved by the 
order of the Ministry of Health of Ukraine of № 555 from 
27.06.2013 “About approval and introduction of medical 
and technical documents on standardization of medical 
care in case of chronic obstructive pulmonary disease” (or-
der with change №270 from 16.04.14 “About amendments 
to the orders of the Ministry of Health of Ukraine “[17]. The 
severity of COPD was consistent with stage II and stage III 
and stage II pulmonary insufficiency (LF). The severity of 
COPD was in stage II-III pulmonary failure (PF).
The examination of EAH patients was carried out in 
accordance with order №384 from 24.05.2012 by Ministry 
of Health of Ukraine “About approval and introduction of 
medical and technological documents and standardiza-
tion of medical care for arterial hypertension” [18]. The 
classification of the Association of pulmonologists and 
cardiologists of Ukraine was used to assess heart failure 
(HF) in patients with CPH. According to which СI of 1 
stage is found in 6 (6.3%) patients, HF of II stage in 84 
(87.4%) and HF of  III stage in 6 (6.3%) patients.
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 The criteria for exclusion from the study were the pres-
ence of symptom hypertension, complications of EAH, 
endocrine diseases requiring correction, kidney pathology, 
systemic diseases of connective tissue, oncological diseases 
and other conditions. Statistical processing of the results 
was carried out by the method of parametric statistics. 
The Student test was used to assess the significance of the 
differences. The difference of the indicators was accepted 
reliably at (Р<0,05), as well as with the nonparametric 
Kolmogorov - Smirnov criterion. Correlation analysis was 
performed by a linear Pearson correlation coefficient meth-
od on a Celeron 650 computer with software SPSS11,0.
RESULTS AND DISCUSSION 
Should note that the study of nitric oxide in the pathogen-
esis of EAH revealed a decrease in basal and stimulated 
production of NO [19]. Nitric oxide has proved ineffective 
in relaxing smooth muscles or reduced endothelium ability 
at all by its production. The patients with CPH with com-
bined pathology (third, fourth groups) have the nitric oxide 
content metabolites was significantly reduced compared 
to patients with CPH without EAH. Thus, the 3rd group it 
has 16.2 ± 1.3 mmol / l (Р1<0.05), in the 4th group - 13.1 ± 
1.2 mmol / l (Р2<0.05), whereas the patients with isolated 
CPH have in the 1st group - 26.5 ± 1.2 mmol / l (Р1 <0.05), 
in the 2nd group - 20.2 ± 1.1 mmol / l( Р2<0,05), the healthy 
persons have 36,3±0,8 mmol / l. So, the rate decreased 
by 10.3 and 7.1 mmol/L compared to the group of CPH 
patients without EAH and healthy individuals. The com-
parison of indicators of the 3rd and 4th group (CPH with 
EAH) reliable a difference between them - 3.1 mmol/l (Р3*/ 
≠) that demonstrates that progressing of HF considerably 
influences damage of function of endotheliocyte, reducing 
synthesis of a vasodilator of nitrogen oxide. Its effect should 
be considered alongside ET-1 in these patients. According 
to the data obtained, in patients with CPH in combination 
with EAH in the stage of compensation (3rd group) the 
level of ET-1 was 5.2 ± 0.1 mmol / l, in decompensation 
(4th group) - 7.8 mmol/l. Whereas in patients with CPH 
without EAH, respectively, 4,0 ± 0,4; 6.2 ± 0.6 mmol/l. It 
increased significantly by 1.2 ± 0.09 mmol/l (Р1<0.05) in 
3rd group and by 1.6 ± 0.06 mmol/l in 4th group. According 
to the obtained data, even in patients with CPH without 
signs of EAH in the stage of decompensation, along with 
the decrease of NO metabolites, an increase of ET-1 is ob-
served, and especially in the combination of pathology in 
the stage of decompensation (7.8 mmol / l), i.e. 1.9 times 
more than for CPH in the non-EAH compensation phase.
This may indicate that several factors, such as arterial 
hypoxemia, increased intra-thoracic pressure (all patients 
had emphysema), and abnormal hemodynamics in the 
small circulatory tract, which are already characteristic 
for patients with COPD without CPH are important in 
the pathogenesis of these shifts. This is confirmed by the 
high degree of correlation in these patients between SaO2 
and the level of metabolites of nitric oxide, ET-1. Study-
ing the parameters of the morphometry of HA, we again 
indirectly evaluate the indices of nitric oxide. Therefore, 
to further study the state of endothelial dysfunction (ED), 
we conducted a non-invasive morphometric research of 
HA. patients with CPH without EAH in comparison with 
the group of healthy individuals already notice changes in 
the parameters of morphometry of HA. Thus, the initial 
diameter of HA in these patients in the stage of compen-
sation increased by 1.3 ± 0.002 mm (Р<0.05) in the stage 
of decompensation - by 1.6 ± 0.01 mm (Р<0.05).
Significantly decreased in patients of the 2nd group of 
EDVD (by 5,0%, Р<0,05), the initial rate of blood flow and 
increased the rate at hyperemia (Р<0,05).
The significantly wider initial diameter of HA was 
determined in patients with CPH and EAH, such as, the 
3rd group by 0.5 mm (Р1< 0.05); the 4th group by 0.8 mm 
(Р2<0.05) in comparison with patients with isolated CPH 
(1st and 2nd group). There were lower levels of dependent 
dilatation flow (DDF) in comparison with the 1st group by 
3.5%, in the patients with the 2nd group by 4.4% (Р<0.05), 
which indicates the depletion of the product nitric oxide 
due to an increase in vasoconstrictor factors. Reduced of 
induced dilation (EIVD), identical, but in a lesser extent. 
At patients of the 3rd group it decreased by 2,0 (Р1<0,05), at 
patients of the 4th group by 2,4% (Р2<0,05) in comparison 
to individuals with HPG without EAH.
In the patients of the 3rd  and 4th groups are noted correla-
tion communication between the level of EIVD and output 
diameter of HA(r = - 0,68, Р<0,05 і r = - 0,70, Р<0,01), and 
also the strong dependence is found between EDVD and 
ET-1 level (r = - 0,72, Р<0,05).
The connection among during of diseases of CPH, COPD 
that is a cause and diameter of HA was studied. It is noted 
that the size of HA is more altered depending on the dura-
tion of COPD. The initial rate of blood flow in patients with 
CPH of the 1st and 2nd groups was 0.66 ± 0.005 m / s and 
0.60 ± 0.002 m / s, the patients with CPH with high blood 
pressure - 0.54 ± 0.006 m / s (Р<0.05) and 0.50 ± 0.003 m / s 
(Р<0.05). The percentage increase in the rate of hyperemia 
also decreased in patients of the 3rd group by 6.6 ± 0.8% 
(Р<0.05) and in patients of 4th group by 19.7 ± 1.0% (Р<0.05).
Thus, summarizing the above data regarding the study 
of ED in patients with CPH in combination with EAH, it 
should be noted that ultrasound studies of HA indicators 
in combination with the level of nitric oxide, ET-1 indicate 
their significant role in the formation of CPH and more 
pronounced changes in ED in side of increasing factors of 
vasoconstruction and inhibition of formation of nitric oxide.
This contributes to the formation of HF, especially in 
patients with comorbid pathology, namely CPH with EAH. 
It should be noted, that EAH contributes significantly to 
the causing of hypertensive heart, so special attention is 
required to the study of the intracardiac hemodynamics 
of the right and left ventricle especially in the combination 
of CPH with EAH.
The research was revealed that patients with CPH com-
bined with EAH even in the phase of compensation have 
significantly reduced CI and PI, a decrease in the rate of 
acceleration of blood flow through the aortic valve (Р<0,05), 
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which led to a decrease in PV by 1.3 times (Р<0,05) in com-
pared to healthy persons, but it remained within the normal 
range (3rd group 50,0±2,5%). These changes indicate a ad-
ditional contribution of the EAH to cause reduced systolic 
function on the period of hypoxia of toxic-infectious and 
metabolic effects of COPD. Even more pronounced were 
the changes revealed in patients with EAH of 4th group.  All 
indicators (СI, PI, Vmax, size of LV) were significantly al-
tered that confirms decrease of EF to 40,5±1,0%. Increasing 
hypertrophy of the posterior LV, especially of IVS, was also 
detected, but they did not reach the values  that are charac-
teristic of isolated EAH. The pathogenesis of these changes 
is explained by a decrease in inflow to the left heart due to 
increased total pulmonary resistance, pulmonary hyperten-
sion in the circulatory system and right ventricular failure.
The diastolic function of  LV changed by relaxation type, 
it  detected in 100% of patients. by relaxation type were also 
detected in 100% of patients. These changes were reflected in 
a decrease in the rate of early diastolic filling (E) to late (A) 
their ratio E/A, especially in patients with CPH in combi-
nation with EAH of 4th group, respectively by 0,3±0,001 m/s 
(Р2 <0,05) and 0,1±0,001 (Р1 <0,05) compared with the 
2nd group of patients with CPH without EAH (Р1 <0,05) with 
increasing IVRT from 0,11±0,002s to 0,16±0,004s (Р2 <0,05). 
Significant thickening of the IVS is noted, which also plays 
a role in the formation of diastolic dysfunction of the LV. 
Violation of diastolic filling of the LV, along with changes in 
systolic function, was accompanied by its dilation by 7.6%. 
Thus, the research showed that systolic dysfunction 
of LV heart is exacerbated by the adherence to essential 
hypertension in the CPH. pressure, decreased myocardial 
contractility on changes in LV, hypoxia, myocardial dystro-
phy, which are already present in COPD patients, are also 
important. Diastolic dysfunction of the LV heart appears 
already on the background of the formation of CPH in 
patients with COPD and is greatly exacerbated with EAH 
attachment and especially due to the development of HF.
CONCLUSIONS
1.  The patients with bronchopulmonary genesis in combi-
nation with EAH are characterized by more pronounced 
changes in ED toward an increasing of the level of va-
soconstrictor factors (ET-1),  decreasing of vasodilators 
(metabolites of nitric oxide), which is naturally observed 
when joining arterial hypertension than in patients with 
isolated CPH and confirmed by ultrasound examination 
of the brachial artery, its high correlation with ED. This 
requires combination treatment to correct these changes 
and improve patients’ prognosis.
2.  The patients with CPH in combination with EAH as an 
indicators of metabolites NO, ET-1, ultrasonography 
of humeral artery indicate substantial contribution in 
progression endothelial dysfunction and circulatory 
insufficiency.
3.  Changes in systolic and diastolic function of the LV the 
degree of which increases with the progressing of HF, 
combined pathology and correlates with the parameters 
of endothelial dysfunction (EFLV – NO2  - NO3 r = 0,72, 
Р<0,05; EFLV  – ЕТ-1 r = 0,64, р<0,05) and deepened due 
to the development of decompensation.
4.  Systolic dysfunction of the left ventricle is exacerbated 
when CPH joins to essential arterial hypertension. In 
addition, to the influence of high blood pressure, hy-
poxia, myocardial dystrophy, which are characteristic 
of patients with bronchopulmonary genesis are also 
important Diastolic dysfunction of the left ventricle 
of the heart appears already on the background of the 
formation of CPH and is greatly progressing in the com-
bined pathology and especially, due to the progressing of 
EF, which is a predictive factor of aggravation.
5.  The chronic pulmonary heart combined with essential 
arterial hypertension mutually exacerbate the disease in 
comparison with patients with isolated chronic pulmo-
nary heart, indicating a syndrome of “mutual burden”, 
which leads to a more severe course of the disease, that 
should be taken into account both in diagnosis and 
treatment.
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